Cadrenal Retains Advisor for Strategic Process
Cadrenal Therapeutics (CVKD) has retained Tungsten Advisors to lead a formal evaluation of strategic alternatives, including potential partnerships and asset sales, as its pipeline matures following FDA alignment on CAD-1005. This development highlights the Company's proactive approach to maximizing shareholder value amidst significant industry interest.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed